Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,02 USD | +3,02% | -1,92% | -26,09% |
30/04 | In8bio, Inc. Doseert eerste patiënt in Fase 2 klinische studie van Inb-400 in nieuw gediagnosticeerd glioblastoma | CI |
10/04 | Top premarket stijgers | MT |
Vakgebied
Aantal werknemers: 31
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lawrence Lamb
FOU | Founder | 70 | 07-05-18 |
William Ho
FOU | Founder | 48 | 07-05-18 |
Patrick McCall
DFI | Director of Finance/CFO | - | 08-02-21 |
Stacey Bilinski
CTO | Chief Tech/Sci/R&D Officer | - | 13-04-22 |
Trishna Goswami
CTO | Chief Tech/Sci/R&D Officer | - | 16-11-21 |
Kate Rochlin
COO | Chief Operating Officer | - | 01-08-20 |
Corporate Officer/Principal | - | 12-07-22 | |
Urvashi Patel
LAW | General Counsel | - | 13-04-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
William Ho
FOU | Founder | 48 | 07-05-18 |
Peter Brandt
BRD | Director/Board Member | 67 | 01-07-19 |
Alan S. Roemer
CHM | Chairman | 54 | 01-09-20 |
Emily Fairbairn
BRD | Director/Board Member | 62 | 04-08-21 |
Corinne Epperly
BRD | Director/Board Member | 46 | 07/12 |
Travis Whitfill
BRD | Director/Board Member | 34 | 07-05-18 |
Luba Greenwood
BRD | Director/Board Member | 45 | 04-08-21 |
Jeremy Graff
BRD | Director/Board Member | - | 01-05-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 44 019 836 | 36 374 814 ( 82,63 %) | 0 | 82,63 % |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-26,09% | 44,9 mln. | |
-3,46% | 102 mld. | |
+1,41% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-15,84% | 21,4 mld. | |
-9,33% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,65% | 16,09 mld. | |
+4,39% | 13,83 mld. | |
+31,35% | 11,97 mld. |
- Beurs
- Aandelen
- Koers INAB
- Onderneming IN8bio, Inc.